Cowan, J.M.

patient metaphase cytogenetics myeloma cytogenetic bortezomib metaphase survival response chromosome summit trial chromosome 13 deletion deletion analysis dexamethasone prognostic status therapy myeloma patients matched-pair impact signi study response rate prognosis prognostic impact high-dose phase jagannath blood b 2m level result barlogie b cancer treatment abnormality marrow chromosome 13 high-dose therapy ficant chromosome 13 abnormalities difference interphase fl uorescence dexamethasone arm leukemia figure barlogie bortezomib-treated patients fl uorescence apex trials response rates analyses signi ficantly high-dose dexamethasone prognostic factor matched-pairs analyses tricot g factor center cycle uorescence table transplantation oncol progression richardson 3- week cycles fi ndings chromosomal abnormalities signi ficant difference 5- week cycles matched-pairs subset analyses matched-pairs analysis 669 patients subset dexamethasone-treated patients summit trial tricot 202 patients ackermann j